Viral Vector and Plasmid DNA Manufacturing Market

Global Viral Vector and Plasmid DNA Manufacturing Market Size

The global viral vector and plasmid DNA manufacturing market, valued at USD 843 million in 2025, is projected to reach USD 937 million in 2026 and USD 2,161 million by 2035, with a CAGR of 9.73% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Viral and non-viral vectors have emerged as indispensable tools for delivering genetic material into target cells, forming the backbone of modern cell therapies and gene therapies. By May 2025, around 30 viral vector–based therapies have received global regulatory approval, while over 500 candidates are undergoing clinical trials in the US. This surge in approvals and ongoing studies has fueled the demand for large-scale viral vector manufacturing. However, this domain is fraught with several challenges, including immunogenicity risks and the complex nature of viral vector characterization. To overcome these hurdles, developers are increasingly exploring the potential of non-viral vectors as safer and more scalable alternatives.

To meet the rising demand for vectors, the industry has introduced several process innovations. Notably, Corning Life Sciences has developed high-density cell culture systems such as HYPERStack and CellSTACKs, which leverage gas-permeable film technology to enhance vector yields. The company has also introduced automation platforms to optimize workflows, reduce manual intervention, and accelerate production timelines. These technological improvements have created momentum for more efficient, consistent, and cost-effective vector manufacturing worldwide.

Presently, over 300 industry and non-industry players across the globe are actively involved so as to support the expanding pipeline of cell therapies, gene therapies, and vector-based vaccines, as per viral vectors and plasmid DNA manufacturing market report. The growth in this sector is further fueled by investments, strategic collaborations, and facility expansions, reflecting a strong commitment towards overcoming production bottlenecks. Collectively, these developments suggest that both viral and non-viral vector manufacturing are poised for strong growth, making them key driver of the next generation of genetic medicines.

Viral Vector and Plasmid DNA Manufacturing Market Segmentation Insights

The viral vector and plasmid DNA manufacturing market analysis also highlights the likely distribution of the current and forecasted opportunity across various segments, such as scale of operation, type of vectors manufactured, application area, therapeutic area, type of manufacturer and geographical regions.

We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios outline different tracks of the industry's evolution.

The viral vector & plasmid manufacturing market is set to grow, fueled by increasing demand for gene therapies, expanding vaccine development initiatives and ongoing technological advancements in vector design and production platforms. Further, our projections show that the market will grow at a significant CAGR in the coming years, supported by expanding clinical pipelines, increasing investments and collaboration activity for scalable production platforms.

Owing to the growing research and development efforts for viral vector-based therapies, the success of early-stage clinical trials and the promising therapeutic potential of viral vector-based therapies, we believe that the viral vector and plasmid DNA manufacturing industry is likely to grow at a steady rate during the forecast period.

Recent Developments in Viral Vector & Plasmid DNA Manufacturing Market

Several recent developments have taken place in the field, and we have outlined some of these below. These developments, even if they arose after our market report’s release, support the overall viral vector and plasmid DNA manufacturing market trends detailed in our analysis.

• In August 2025, ProBio launched GMP AAV manufacturing services at its 128,000 sqft facility integrating plasmid DNA production, AAV vector manufacturing, and aseptic fill/finish.
• In July 2025, ProBio entered into a collaboration with ACT Therapeutics for the development and production of plasmid and virus vectors for the latter's advanced CAR-T platform pipeline.
• In May 2025, AGC Biologics entered into a collaboration with Quell Therapeutics with an aim to produce lentiviral vector materials for Quell’s engineered T-regulatory cell therapies targeting severe immune disorders, leveraging AGC's ProntoLVV™ platform and Milan facility for GMP manufacturing and clinical trials.
• In March 2025, CHO Plus was awarded a US patent for using cell hybrids in viral vector manufacturing, aimed at reducing AAV production costs while improving product quality and efficiency in the plasmid DNA and viral vector supply chain.
• In February 2025, Fuse Vectors secured EUR 4.9 million in pre-seed financing to advance its cell-free viral vector technology for gene therapy development, enhancing innovation in viral vector and plasmid DNA manufacturing processes.
• In February 2025, Novartis opened a USD 41.2 million fully automated viral vector facility in Slovenia for cell and gene therapies targeting cancer and serious diseases, equipped with robotics for end-to-end production; total investment in Slovenia reaches USD 3.6 billion.

Industry Experts on Viral Vector and Plasmid DNA Manufacturing

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Chief Executive Officer, mid-sized company, Netherlands
• Chief Executive Officer and Chief Scientific Officer, small company, Germany
• Former Executive and Scientific Director, small company, Belgium
• Co-Founder and President, mid-sized company, France
• Former Director, Netherlands-based company
• Director, Massachusetts-based organization
• Former Scientific Director, France-based organization
• Former Managing Director, small company, Japan
• Scientific Director, small company, US
• Key Account Management, mid-sized company, Germany
• Head of Project Management, small company, Germany
• Director of Business Development, small company, US
• ATMP Key Account Manager, France-based organization
• Chief Scientific Officer, small company, France
• Director of Marketing and Technical Support, mid-sized company, France
• Head of Communications, mid-sized company, Spain
• Independent Consultant

Viral vector and plasmid DNA domain will mark a turning point in 2025. Industry expert’s states, “Over the past few years, interest advancements in gene therapy and cell-based treatments are revolutionizing the treatment of multiple disorders.”

Viral Vector and Plasmid DNA Manufacturing Market Share Insights

Market Share by Scale of Operation: Clinical Segment Promises High Revenue

• This segment highlights the distribution of market across various scales of operation such as preclinical, clinical and commercial. As per viral vector and plasmid DNA manufacturing market analysis, in 2026, the clinical segment occupies the higher market share (50%). This is due to the high demand from numerous ongoing gene and cell therapy clinical trials.
• It is worth mentioning that the commercial stage segment is likely to witness a significant growth rate with a CAGR of 13% during the forecast period. This is due to the evolving cell and gene therapy landscape, where most of the therapies are under later stages of development and are likely to get into the market soon.

Market Share by Type of Vector Manufactured: Lentiviral Vector Segment Holds the Largest  Share

• Based on type of vector manufactured, the overall market includes AAV vectors, adenoviral vectors, lentiviral vectors, retroviral vectors, non-viral vectors and other vectors. In 2026, lentiviral vector segment occupies the higher market share (25%). This is due to the fact that several lentiviral vector based gene therapies and cell therapies currently in the late stage of clinical development.
• Further, the market is likely to witness a substantial increase in the share of AAV vectors market share, growing at a CAGR of 13% during the forecast period. This is ascribed to advantages offered by AAV vectors, such as efficient transduction of various cell types and their ability to deliver large amounts of DNA.

Market Share by Application Area: Gene Therapy Segment Shows Dominance

• Based on application area, the overall marker includes cell therapy, gene therapy and vaccine. In 2026, vectors that are used in gene therapy segments occupy the highest market share (49%). This is due to the rising number of approved gene therapies for multiple indications, which has substantially increased the demand for high-quality vector production.
• Further, the market is likely to witness a substantial increase in the share of vectors that are used for cell therapy manufacturing, growing at a CAGR of 11% during the forecast period. This trend is due to an increasing number of therapies that are currently in clinical trials.

Market Share by Therapeutic Area: Oncological Disorders Segment Holds the Largest Market Share

• As per viral vector and plasmid DNA manufacturing market forecast, in 2026, vector-based therapies for the treatment of oncological disorders occupy the highest market share (47%), due to the growing incidence of such disorders, across the globe.
• Further, vector-based therapies for the treatment of ophthalmic disorders is likely to grow at a CAGR of 31% during the forecast period. This is due to the increasing number of cell and gene therapies approvals for eye related disorders.

Market Share by Type of Manufacturer: Contract Manufacturing Segment Will Continue to Grow

• This segment highlights the distribution of market across various types of manufacturers, such as contract manufacturing and in-house manufacturing. In 2026, contract manufacturer segment (57%) is likely to dominate the market and is expected to grow at a higher CAGR (11%) during the forecast period.
• This trend is due to the potential of CMOs to offer scalability and flexibility, enabling them to swiftly adapt to changing manufacturing requirements and manage rising production demands.

Which Geographical Regions and Countries are Emerging as Growth Hotspots for Viral Vector Production?

• In 2026, North America (54%) holds the higher market share. This is due to the advanced healthcare infrastructure and research ecosystem in North America.
• Conversely, the market in Asia-Pacific, and Middle East and North Africa is likely to grow at a relatively higher CAGR (11% each), during the forecast period. This is due to the rising incidence rate of chronic disorders (including neurological disorders, genetic disorders and rare diseases) and the increasing demand for effective and advanced therapeutics.

Viral Vector and Plasmid DNA Manufacturing Market Key Takeaways

The “Viral Vector and Plasmid DNA Manufacturing Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of viral vector manufacturing (industry players) landscape, non-viral vector manufacturing (industry players) landscape, vector manufacturing (non-industry players) landscape, demand and supply analysis and market forecast and opportunity analysis, during the forecast period. 

Viral Vector and Plasmid DNA Manufacturing Market Competitive Landscape 

The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the healthcare market. Key takeaways of the market report have been briefly discussed below.

Viral Vector Manufacturing (Industry Players) Landscape

The market landscape is concentrated with the presence of over 130 viral vector manufacturers. Of these, 45% of the companies have been established post-2010 indicating the growing interest of stakeholders in this domain. Notable examples of companies (established post- 2010, in alphabetical order) include 4D Molecular Therapeutics, Abeona Therapeutics, Adverum Biotechnologies, AGC Biologics, Andelyn Biosciences, Autolus and Beacon Therapeutics. 

Notably, 91% of the viral vector therapies are currently in clinical stages of development, with 80% of therapies in preclinical stages. Further, majority of the therapies are manufactured by contract manufacturers based in different countries across the globe.

Plasmid DNA Manufacturing (Industry Players) Landscape 

The current landscape presents over 100 well-established players and new entrants that are involved in manufacturing non-viral vectors. Further, the landscape features a fragmented structure, with very large, large, mid-sized and small players headquartered across different regions.

It is worth noting that majority (close to 60%) of the manufacturers have their headquarters in North America, owing to the robust research initiatives and substantial investments made by the manufacturers in this region. 

Vector Manufacturing (Non-Industry Players) Landscape

The current market landscape features over 80 organizations and more than 80% of organizations have the required capabilities to manufacture AAV vectors. Notably, close to 40% of the organizations have capability to manufacture vectors at preclinical and clinical stages. Further, majority of the organizations (90%) actively manufacture vectors for use in gene therapies, followed by cell therapies. 

Technology Landscape

The technology landscape includes over 100 technologies that are utilized for manufacturing various types of vectors. Presently, 86% of the technologies are manufacturing vectors at clinical stage, followed by preclinical (63%). Additionally, majority (83%) of the technologies are being utilized for manufacturing vectors that can be used in gene therapy applications.

Viral Vector and Plasmid DNA Manufacturing Market Size Analysis: Global Market to Grow at 9.73% CAGR

The global viral vector manufacturing market size is likely to be worth $ 937 million in 2026 and will reach $ 2,161 million by 2035. In terms of scale of operation, the global market highlights distribution of preclinical, clinical and commercial scales. In 2026, the clinical segment dominates the market and holds 50% of the market share, owing to the large pipeline of viral vector-based therapies in various stages of clinical trials. Further, the market size for commercial segment is likely to grow at a relatively higher CAGR of 13% during the forecast period.

Regional Analysis: Which Region Holds the Largest Share of the Viral Vector and Plasmid DNA Manufacturing Market?

North America is Leading the Market

North American companies are likely to dominate the global viral vector and plasmid DNA manufacturing market by 2035, owing to the robust research and development activities, coupled with increasing adoption of viral vector manufacturing for a wide range of therapies. Notably, major industry CMOs such as Cytiva, Pfizer, Resilience and uniQure have viral vector manufacturing facilities in the US.

Asia-Pacific: An Emerging Growth Spot

The market in Asia-Pacific is likely to grow at a relatively high CAGR (11%), during the forecast period till 2035. This is a result of increased healthcare spending and government initiatives to improve healthcare infrastructure, along with a surge in number of clinical trials for viral vector-based therapies in this region.

What are the Key Drivers of Viral Vector and plasmid DNA Manufacturing Market?

The increasing number of gene therapy clinical trials and market approvals are the key drivers for demand for viral and non-viral vectors, as development of each therapy requires a consistent supply of high-quality vectors. Further, technological advancements in vector engineering and manufacturing processes, such as the use of improved cell lines and purification techniques, have significantly enhanced production capacity, vector quality, and safety profiles. These advancements also contribute to cost reduction, facilitate regulatory compliance, and support the expanding pipeline of gene therapy products.

Additionally, the rising prevalence of genetic diseases and the growing investment in research and development within the gene therapy sector contribute significantly to the market's growth, creating a strong demand for viral vector manufacturing services.

What are the Key Challenges Facing the Viral Vector and Plasmid DNA Manufacturing Market?

The vector-based manufacturing market faces several challenges primarily due to high complex manufacturing process demanding specialized expertise, advanced equipment and stringent quality controls.

Latest Viral Vector and Plasmid DNA Manufacturing Market Trends

Rising Partnership and Collaborations Amongst the Industry Stakeholders to Foster Progress and Innovation in Expanding their Capabilities

Stakeholders in this domain have entered into numerous partnerships and collaborations, allowing them to expand their respective offerings and enhance their capabilities and visibility in this domain. In terms of partnerships, product manufacturing agreement, acquisition, licensing agreement and product development and manufacturing agreement have emerged as the most popular engagement models.

In July 2025, ProBio entered into a collaboration with ACT therapeutics for the development and production of plasmid and virus vectors for the first pipeline of latter's advanced CAR-T platform.

In May 2025, Forge Biologics collaborated with Fractyl Health to develop and produce AAV vectors, supporting the advancement of Fractyl Health’s gene therapy platform for the treatment of metabolic diseases.

Facility Expansions to Support the Growing Demand

Players in this domain are expanding their capability in order to enhance their portfolio. For viral vector and plasmid DNA manufacturing, facility expansion has emerged as the most popular engagement model.

In July 2025, ProBio, a subsidiary of GenScript Biotech, opened its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell, New Jersey; a 128,000 sqft, GMP-compliant facility. The purpose is to manufacture high-quality plasmid DNA and viral vectors, including adeno-associated virus and lentiviral vector platforms.

In February 2025, Novartis opened a USD 41.2 million fully automated viral vector facility in Slovenia, marking its first step into viral vector production in Europe. The new site, called VIFA One will support the development of cell and gene therapies for cancer and other serious diseases. Equipped with advanced robotics, the plant can manage all stages of production at a single location. With this launch, Novartis’ total investment in Slovenia has reached USD 3.6 billion, underscoring the company’s long-term commitment to the country’s biopharmaceutical ecosystem.

Technological Advancements to Fuel Innovation and Drive Efficiency

Technological advancements are rapidly transforming the viral vector manufacturing landscape. Innovations in cell culture technologies, such as the development of improved cell lines and optimized culture conditions, have significantly increased vector yields and reduced production costs. Advancements in downstream processing, including chromatography and filtration techniques, have enhanced the purity and safety of viral vectors.

Viral Vector Manufacturing Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the viral vector & plasmid manufacturing industry, across different geographies. Amongst other elements, the market report includes:

• An Infographic Executive Summary (link)
• Market Landscape of Viral Vector Manufacturers (Industry Players)
• Market Landscape of Non-Viral Vector Manufacturers (Industry Players)
• Market Landscape of Vector Manufacturers (Non-Industry Players)
• Technology Landscape
• Company Competitiveness Analysis
• Partnerships and Collaborations
• Recent Expansions
• Strategic Partner Analysis
• Key Insights
• Go-No-Go Framework
• Capacity Analysis
• Demand and Supply Analysis
• Market Forecast and Opportunity Analysis

Viral Vector and Plasmid DNA Manufacturing Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2021
Forecast Period	Till 2035
Market Size 2025	$ 843 Million
Market Size 2035	$ 2,161 Million
CAGR (Till 2035)	9.73%
Scale of Operation	Preclinical Clinical Commercial
Application Area	Cell Therapies Gene Therapies Vaccines
Type of Vector Manufactured	AAV Vectors Adenoviral Vectors Lentiviral Vectors Retroviral Vectors Non-viral Vectors Other Vectors
Therapeutic Area	Oncological Disorders Rare Disorders Immunological Disorders Neurological Disorders Sensory Disorders Metabolic Disorders Blood Disorders Musculoskeletal Disorders Infectious Diseases Ophthalmic Disorders Other Disorders
Type of Manufacturer	In-house Manufacturers Contract Manufacturing Organizations
Geographical Regions	North America Europe Asia-Pacific Middle East and North Africa  Latin America
Excel Data Packs  (Complimentary)	Viral Vector Manufacturing (Industry Players) Landscape Non-Viral Vector Manufacturing (Industry Players) Landscape Vector Manufacturing (Non-Industry Players) Landscape Technology Landscape Company Competitiveness Analysis Partnerships and Collaborations Recent Expansions Strategic Partner Analysis Key Insights Go-No-Go Framework Capacity Analysis Demand and Supply Analysis Market Forecast and Opportunity Analysis
Key Players Profiled	Advanced BioScience Laboratories AGC Biologics  Aldevron  Celonic Catalent Biologics Charles River Laboratories Novartis Oxford BioMedica (A complete list of more than 190 companies is available in the report)
PowerPoint Presentation  (Complimentary)	Available
Customization Scope	15% Free Customization